Setmelanotide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Setmelanotide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Setmelanotide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 2-3 mg daily Once daily | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection daily | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Before bed or morning (fasted) | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. In March 2026, FDA approved an expanded indication for acquired hypothalamic obesity in adults and pediatric patients aged 4+. The Phase 3 TRANSCEND trial showed -18.4% placebo-adjusted BMI reduction. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Setmelanotide vs Eloralintide
What is the difference between Setmelanotide and Eloralintide?
Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Setmelanotide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Setmelanotide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Setmelanotide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Setmelanotide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.